APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
International Workshop of Scleroderma Research
Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases associated with SSc-ILD
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
